SUVmax—Δ makes the difference-Reference-Cited by-同舟云学术

SUVmax—Δ makes the difference

Published:2022-06-24 Issue:2 Volume:35 Page:
ISSN:1569-9285
Container-title:Interactive CardioVascular and Thoracic Surgery
language:en
Short-container-title:

Author:

Aigner Clemens¹^ORCID,Hautzel Hubertus²,Ploenes Till¹

Affiliation:

1. Department of Thoracic Surgery, West German Cancer Center, University Medicine Essen , Essen, Germany

2. Department of Nuclear Medicine, West German Cancer Center, University Medicine Essen , Essen, Germany

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,Surgery

Link

https://academic.oup.com/icvts/advance-article-pdf/doi/10.1093/icvts/ivac169/44246100/ivac169.pdf

Reference10 articles.

1. Role of fluorodeoxyglucose-positron emission tomography in predicting the pathological response and prognosis after neoadjuvant chemoradiotherapy for locally advanced non-small-cell lung cancer;Tanahashi;Interact CardioVasc Thorac Surg

2. Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial;Guberina;Eur J Nucl Med Mol Imaging,2019

3. Standardized uptake decrease on [18F]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable stage IIIA/B non-small-cell lung cancer;Pöttgen;J Clin Oncol,2016

4. Predictive and prognostic role of metabolic response in patients with stage III NSCLC treated with neoadjuvant chemotherapy;Castello;Clin Lung Cancer,2020

5. Role of various semiquantitative parameters of 18F-FDG PET/CT studies for interim treatment response evaluation in nonsmall-cell lung cancer;Sharma;Nucl Med Commun,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-reactive protein as robust laboratory value associated with prognosis in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiochemotherapy;Scientific Reports;2024-06-14